Resources | endTB

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited. We report end-of-treatment outcomes for MDR/RR-TB patients from a 2015–2018 multi-country cohort that received a regimen consistent with current 2022 WHO updated recommendations and describe the complexities of comparing regimens.

endTB Observational Study

Read more about Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis

ABSTRACT

RATIONALE: Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform the optimal duration of bedaquiline.

OBJECTIVES: We emulated a target trial to estimate the effect of three bedaquiline duration treatment strategies (6 months, 7-11 months, ≥ 12 months) on the probability of successful treatment among patients receiving a longer individualized regimen for multidrug-resistant tuberculosis.

endTB Observational Study

Read more about Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

We used simulated data and data from the endTB observational cohort to investigate the potential for bias when extending baseline culture intervals past treatment initiation. We evaluated bias in the proportion with six-month conversion.

endTB Observational Study

Read more about Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Treatment success calculated by algorithms had high concordance with treatment success assigned by clinicians (95.8 and 97.7% for failure-dominant and success-dominant algorithms, respectively). The frequency and pattern of the most common discrepancies varied by country.

endTB Observational Study

Read more about Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Pre-print of the endTB results manuscript : “Nine-month, all-oral regimens for rifampin-resistant tuberculosis.”

Find for download the pre-print of the endTB results manuscript (PDF format).

More information on the endTB clinical trial results page.

endTB Clinical Trial

Read more about Pre-print of the endTB results manuscript : “Nine-month, all-oral regimens for rifampin-resistant tuberculosis.”

PowerPoint slides of the endTB trial results presentations at the Union World Conference

You can download the PowerPoint slides of our endTB trial results presentations at the Union World Conference, 15-18 November 2023.

More details on the endTB clinical trial results at this link: https://endtb.org/endtb-clinical-trial-results

endTB Clinical Trial

Read more about PowerPoint slides of the endTB trial results presentations at the Union World Conference

Publication: Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Background: Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline and delamanid, and repurposed drugs clofazimine and linezolid, show great promise for combination in shorter, less-toxic, and effective regimens.

endTB-Q Clinical Trial

Read more about Publication: Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

endTB trial results presentations at the Union World Conference

More than six years ago, the endTB clinical trial was launched to find shorter, more tolerable, injection-free treatments for people with MDR-TB. Join us at the Union World Conference 2023 in Paris for the endTB clinical trial results presentation!

endTB Clinical Trial

Read more about endTB trial results presentations at the Union World Conference

endTB trial results presentations at the Union World Conference

You can download our flyer on the endTB trial results presentations at the Union World Conference, 15-18 November 2023

Read more about endTB trial results presentations at the Union World Conference

Technical Basis of the endTB Observational Study (EN/RU/ES/FR)

endTB Observational Study had sites in 17 countries. In each country, sites enrolled patients on treatment with bedaquiline and delamanid according to National TB Program guidelines, while collecting clinical and bacteriological data on efficacy and safety. Because many of the endTB Observational Study tools were found to be useful for clinicians and programs that were starting to use the new TB drugs and regimens, we made them freely available at the endTB website.

endTB Observational Study

Read more about Technical Basis of the endTB Observational Study (EN/RU/ES/FR)